Capricor Therapeutics
CAPR
31 hedge funds and large institutions have $18.1M invested in Capricor Therapeutics in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 3 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
3% more funds holding
Funds holding: 30 → 31 (+1)
3.81% less ownership
Funds ownership: 19.23% → 15.42% (-3.8%)
12% less capital invested
Capital invested by funds: $20.5M → $18.1M (-$2.42M)
70% less call options, than puts
Call options by funds: $683K | Put options by funds: $2.25M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$415K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$308K |
| 3 |
State Street
Boston,
Massachusetts
|
+$304K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$141K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$3.53M |
| 2 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
-$1.26M |
| 3 |
BlackRock
New York
|
-$178K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$119K |
| 5 |
MHS
M Holdings Securities
Portland,
Oregon
|
-$94K |
CAPR Hedge Fund Activity: Q2 2021 in Review
31 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q2 2021, worth a combined $18.1M — down 12% from $20.5M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CAPR positions and 3 closed out — a net gain of 1 holder — while 14 added to existing stakes and 9 trimmed.
The largest buyer was GSA Capital Partners, adding an estimated $415K. The largest seller was Oracle Investment Management, cutting an estimated $3.53M.
- 31 institutional investors held Capricor Therapeutics (CAPR) as of Q2 2021, up from 30 in Q1 2021.
- Funds reported $18.1M of Capricor Therapeutics stock for Q2 2021, down 12% quarter-over-quarter.
- 4 funds opened new Capricor Therapeutics positions in Q2 2021 and 3 closed out, a net change of +1 holder.
- The largest Capricor Therapeutics buyer in Q2 2021 was GSA Capital Partners, an estimated $415K added.
- The largest Capricor Therapeutics seller in Q2 2021 was Oracle Investment Management, an estimated $3.53M sold.
Based on aggregated 13F filings for Q2 2021.